Clinical Trials on Neuroendocrine Neoplasms (Tumours)

Total 108821 results

Australasian Gastro-Intestinal Trials Group

Completed

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study (CONTROL NETS)

Midgut Neuroendocrine Tumours | Pancreatic Neuroendocrine Tumours

Australia
King's College Hospital NHS Trust
Ampersand Health Ltd; Neuroendocrine Cancer UK

Recruiting

Mobile Application to Collect PRO Data in NET Patients

Neuroendocrine Neoplasms (Tumours)

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Neuroendocrine Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
Francesco De Cobelli

Completed

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

Pancreatic Neuroendocrine Tumor

Italy
TaiRx, Inc.

Active, not recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine Neoplasm

Taiwan
Amr Mohamed MD
Novatek Pharmaceuticals

Active, not recruiting

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Neuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

United States
Grupo Espanol de Tumores Neuroendocrinos

Active, not recruiting

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Neuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

Spain
Ipsen

Completed

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (CALM-NET)

NeuroEndocrine Tumours

United Kingdom
University of Roma La Sapienza

Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (REBORN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

Italy
Arcispedale Santa Maria Nuova-IRCCS

Completed

68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

Neuroendocrine Tumours

Austria, Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
University of Washington
Eli Lilly and Company

Recruiting

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Metastatic Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Digestive System Neuroendocrine Tumor | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine... and other conditions

United States
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Ipsen

Terminated

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours (PRELUDE)

Neuroendocrine Tumours

United Kingdom, France, Germany, Australia, Italy
Dana-Farber Cancer Institute
Bayer; Novartis

Completed

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
National Cancer Institute, Naples

Recruiting

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM)

Lung Neuroendocrine Neoplasm | GEP Neuroendocrine Tumor

Italy
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)

Neuroendocrine Tumours

Italy
Vanquish Oncology, Inc.
University of Illinois at Chicago

Completed

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Solid Tumor | Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor

United States
University of Iowa
Patient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaborators

Enrolling by invitation

Neuroendocrine Tumors - Patient Reported Outcomes (NET-PRO)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation; Paul Scherrer Institute (PSI)

Recruiting

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)

Neuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Neuroendocrine Tumor

United States
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3

China
Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Completed

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

Intermediate Grade Lung Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Functional Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Duodenal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor | Nonfunctional Pancreatic Neuroendocrine... and other conditions

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Federico II University

Completed

The Management of Neuroendocrine Tumours: A Nutritional Viewpoint. (NetNutr)

Mediterranean Diet | Neuroendocrine Tumours (NETs)

Italy
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Active, not recruiting

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Neuroendocrine Tumor, Malignant

United States
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Yusuf Menda
National Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...

Enrolling by invitation

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
University Hospital, Bordeaux
Advanced Accelerator Applications

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)

Neuroendocrine Tumor | Liver Metastases | Neuroendocrine Gastroenteropancreatic Tumour

France
Ipsen

Completed

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (PREF-NET)

Neuroendocrine Tumours (NET)

United Kingdom
Vanderbilt-Ingram Cancer Center

Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Digestive System Neuroendocrine Tumor G1 | Digestive System Neuroendocrine Tumor G2

United States
University of Iowa
Novartis

Not yet recruiting

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Neuroendocrine Tumors | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
Peter Anderson

Completed

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor | Recurrent Neuroendocrine Tumor

United States
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Roswell Park Cancer Institute

Not yet recruiting

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Malignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Neoplasm

United States
University Hospital, Antwerp
Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA)

Gastroenteropancreatic Neuroendocrine Tumor

Netherlands, Belgium
H. Lee Moffitt Cancer Center and Research Institute

Completed

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Pancreatic Neoplasm | Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | Unresectable Pancreatic Neuroendocrine Tumor

United States, Canada
Maastricht University Medical Center

Unknown

Everolimus TDM to Predict Long Term Toxicity (Foresight)

Renal Cell Carcinoma | Breast Cancer | Neuroendocrine Neoplasm of Lung | Pancreatic Neuroendocrine Tumour | Gastrointestinal Neuroendocrine Tumour

Netherlands

Clinical Trials on Neuroendocrine Neoplasms (Tumours)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations